| Ytd | -8.42% | |
| 1y | 17.82% |
| Open | 19.44 | Prev Close | 19.54 | Low | 19.00 | High | 19.46 | Mkt Cap | 1.72B |
| Vol | 378.78K | Avg Vol | 1.79M | EPS | -2.51 | P/E | N/A | Forward P/E | -23.95 |
| Beta | 0.40 | Short Ratio | 15.85 | Inst. Own | 126.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 20.87 | 200-d Avg | 20.89 | 1yr Est | 37.55 |
SNDX News
BlackRock Inc. bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts revea
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the pr
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight an
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Con
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the
– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors?
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SND
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Le
Syndax Pharmaceuticals NASDAQ: SNDX used a company R&D event to outline expansion plans for its appr
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical rese
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SND
Syndax has transitioned into a two-product commercial oncology company with growing revenue and stro
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or K
– High response rates observed with the all-oral combination in a heavily pretreated population, inc
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or K
– High response rates observed with the all-oral combination in a heavily pretreated population, inc
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resume
Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovat
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SND
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the pr
Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight an
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.48) per share which beat the a
Goldman Sachs analyst Corinne Johnson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy a
Mizuho analyst Salim Syed maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Outperform and lo
